Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

被引:127
作者
Valenti, Luca [1 ,2 ]
Bugianesi, Elisabetta [3 ]
Pajvani, Utpal [4 ]
Targher, Giovanni [5 ,6 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med & Metab Dis, Milan, Italy
[2] Univ Milan, Dept Pathophysiol & Transplantat, Via Francesco Sforza 35, I-20122 Milan, Italy
[3] Univ Turin, AOU Citta Salute & Sci, Dept Med Sci, Div Gastroenterol, Turin, Italy
[4] Columbia Univ, Div Endocrinol, New York, NY USA
[5] Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy
[6] Azienda Osped Univ Integrata Verona, Verona, Italy
关键词
genetics; insulin resistance; nonalcoholic fatty liver disease; pathophysiology; type; 2; diabetes; HEPATIC GLUCOKINASE EXPRESSION; TRANSCRIPTION FACTOR FOXO1; INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; CONFERS SUSCEPTIBILITY; CARDIOVASCULAR-DISEASE; LIPID-METABOLISM; GENE-EXPRESSION; UNITED-STATES; HEPATOCELLULAR-CARCINOMA;
D O I
10.1111/liv.13185
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Growing epidemiological evidence suggests that nonalcoholic fatty liver disease (NAFLD) is an early predictor of and determinant for the development of type 2 diabetes and other features of the metabolic syndrome. This finding may have important clinical implications for the diagnosis, prevention and treatment of type 2 diabetes and its chronic complications. However, given the complex and bi-directional relationships between NAFLD, insulin resistance and chronic hyperglycaemia, it is extremely difficult to distinguish whether NAFLD is a cause or a consequence of insulin resistance and type 2 diabetes. Indeed, at the molecular level, hepatic lipogenesis and hepatic glucose production depend on differentially regulated branches of the insulin signalling pathway. Furthermore, genetic studies suggest that excess hepatic fat is associated with progressive liver disease, but does not always increase the risk of incident type 2 diabetes. Here, we will briefly review the epidemiological, pathophysiological and molecular evidence linking NAFLD to the development of type 2 diabetes. We will also discuss some recent genetic and therapeutic advances that seem to challenge a causal role of NAFLD in the pathogenesis type 2 diabetes, and propose a working hypothesis to explain this apparent conundrum. In conclusion, progressive liver disease and type 2 diabetes are divergent though inter-related consequences of insulin resistance and the metabolic syndrome.
引用
收藏
页码:1563 / 1579
页数:17
相关论文
共 136 条
  • [1] Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans
    Adkins, A
    Basu, R
    Persson, M
    Dicke, B
    Shah, P
    Vella, A
    Schwenk, WF
    Rizza, R
    [J]. DIABETES, 2003, 52 (09) : 2213 - 2220
  • [2] New Insights into mTOR Signaling: mTORC2 and Beyond
    Alessi, Dario R.
    Pearce, Laura R.
    Garcia-Martinez, Juan M.
    [J]. SCIENCE SIGNALING, 2009, 2 (67) : pe27
  • [3] Dissociation Between Intrahepatic Triglyceride Content and Insulin Resistance in Familial Hypobetalipoproteinemia
    Amaro, Anastassia
    Fabbrini, Elisa
    Kars, Marleen
    Yue, Pin
    Schechtman, Kenneth
    Schonfeld, Gustav
    Klein, Samuel
    [J]. GASTROENTEROLOGY, 2010, 139 (01) : 149 - 153
  • [4] Combined Effect of Nonalcoholic Fatty Liver Disease and Impaired Fasting Glucose on the Development of Type 2 Diabetes A 4-year retrospective longitudinal study
    Bae, Ji Cheol
    Rhee, Eun Jung
    Lee, Won Young
    Park, Se Eun
    Park, Cheol Young
    Oh, Ki Won
    Park, Sung Woo
    Kim, Sun Woo
    [J]. DIABETES CARE, 2011, 34 (03) : 727 - 729
  • [5] Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
    Ballestri, Stefano
    Zona, Stefano
    Targher, Giovanni
    Romagnoli, Dante
    Baldelli, Enrica
    Nascimbeni, Fabio
    Roverato, Alberto
    Guaraldi, Giovanni
    Lonardo, Amedeo
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 936 - 944
  • [6] The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver
    Beer, Nicola L.
    Tribble, Nicholas D.
    McCulloch, Laura J.
    Roos, Charlotta
    Johnson, Paul R. V.
    Orho-Melander, Marju
    Gloyn, Anna L.
    [J]. HUMAN MOLECULAR GENETICS, 2009, 18 (21) : 4081 - 4088
  • [7] PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms
    Brognard, John
    Sierecki, Emma
    Gao, Tianyan
    Newton, Alexandra C.
    [J]. MOLECULAR CELL, 2007, 25 (06) : 917 - 931
  • [8] The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
    Brown, Nicholas F.
    Stefanovic-Racic, Maja
    Sipula, Ian J.
    Perdomo, German
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (11): : 1500 - 1507
  • [9] Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
    Browning, JD
    Szczepaniak, LS
    Dobbins, R
    Nuremberg, P
    Horton, JD
    Cohen, JC
    Grundy, SM
    Hobbs, HH
    [J]. HEPATOLOGY, 2004, 40 (06) : 1387 - 1395
  • [10] Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
    Bugianesi, E
    Gastaldelli, A
    Vanni, E
    Gambino, R
    Cassader, M
    Baldi, S
    Ponti, V
    Pagano, G
    Ferrannini, E
    Rizzetto, M
    [J]. DIABETOLOGIA, 2005, 48 (04) : 634 - 642